SARS Cov2, Immune Response
Conditions
Brief summary
To date, nearly 2 million people, including at least 100,000 in France, have been infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This infection is very heterogeneous in nature, ranging from asymptomatic forms to acute respiratory distress syndrome patterns in 6.1% of cases, leading to an estimated overall mortality of 5.2%. Apart from age, few risk factors for a pejorative evolution have been identified: arterial hypertension, diabetes, cardiovascular history, obesity and chronic respiratory pathology in particular. The median incubation period is 5 days and the median time between the appearance of the first symptoms and the onset of hypoxia requiring admission to intensive care is 7 to 12 days. The mechanisms involved in the occurrence of these secondary worsening patterns are unclear. One hypothesis is that it is related to an inappropriate inflammatory response rather than a direct cytopathic effect of the virus. The objective of this study is to measure the intensity of the T lymphocyte response in patients hospitalized for Cov2 SARS infection in order to determine whether the intensity of the response is associated with worsening of symptoms.
Interventions
BIOLOGICALBlood sample collection
Additional blood volumes taken during a routine care blood test: * 1 dry tube 5 mL for isolation and freezing of serum * 1 x 5 mL EDTA tube to isolate and freeze plasma * 8 heparinized 6 mL tubes for flow cytometry study
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Person having given his or her non-opposition * Patient hospitalized with an SARS-Cov2 infection proven by virological sampling (nasopharyngeal or sputum PCR) less than 8 days old.
Exclusion criteria
* Person subject to a legal protection measure (curatorship, guardianship) * Person subject to a safeguard measure of justice * Pregnant, parturient or breastfeeding woman * Major incapable or incapable of giving consent * Minor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of circulating Th1 lymphocytes | Until the end of the study, about 12 months. | Flow cytometry measurement of the percentage of circulating Th1 lymphocytes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum IFN concentrations-γ, CXCL9, CXCL10, CXCL11 | Until the end of the study, about 12 months. | Immunofluorimetric measurement of serum concentrations of IFN-γ, CXCL9, CXCL10, CXCL11 |
Countries
France
Outcome results
None listed